12 Month Price Forecast For AMRX
Distance to AMRX Price Forecasts
AMRX Price Momentum
🤔 Considering Amneal (AMRX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 2:28 AM UTC
AMRX Analyst Ratings & Price Targets
Based on our analysis of 12 Wall Street analysts, AMRX has a consensus that is bullish. The median price target is $10.50, with forecasts ranging from $9.00 to $12.00. Currently, there are 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With AMRX currently trading at $8.52, the median price forecast suggests a 23.2% upside. The most optimistic forecast comes from Les Sulewski at Truist Securities, projecting a 40.8% upside, while Chris Schott at JP Morgan provides the most conservative target, suggesting a 5.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMRX Analyst Consensus
AMRX Price Target Range
Latest AMRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 11, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $11.00 |
| Oct 2, 2024 | Truist Securities | Les Sulewski | Buy | Maintains | $12.00 |
| Sep 6, 2024 | JP Morgan | Chris Schott | Neutral | Upgrade | $9.00 |
| Aug 13, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $10.00 |
| Aug 12, 2024 | Truist Securities | Les Sulewski | Buy | Maintains | $10.00 |
| May 6, 2024 | Goldman Sachs | Nathan Rich | Buy | Maintains | $8.00 |
| May 6, 2024 | Truist Securities | Les Sulewski | Buy | Reiterates | $9.00 |
| Mar 21, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $8.00 |
| Mar 4, 2024 | Goldman Sachs | Nathan Rich | Buy | Maintains | $6.25 |
| Jan 29, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $8.00 |
| Nov 8, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $7.00 |
| Sep 6, 2023 | Truist Securities | Gregory Fraser | Buy | Reiterates | $6.00 |
| Aug 7, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $5.00 |
| Aug 7, 2023 | Barclays | Balaji Prasad | Overweight | Maintains | $5.00 |
| Aug 7, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $6.00 |
| May 8, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $3.00 |
| Mar 29, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $4.00 |
| Mar 10, 2023 | Barclays | Balaji Prasad | Overweight | Maintains | $4.00 |
| Mar 3, 2023 | Goldman Sachs | Nathan Rich | Buy | Maintains | $3.00 |
| Mar 3, 2023 | BMO Capital | Gary Nachman | Market Perform | Maintains | $4.00 |
Stocks Similar to Amneal Pharmaceuticals Inc
The following stocks are similar to Amneal based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amneal Pharmaceuticals Inc (AMRX) Financial Data
Amneal Pharmaceuticals Inc has a market capitalization of $3.95B with a P/E ratio of 89.8x. The company generates $2.68B in trailing twelve-month revenue with a -6.9% profit margin.
Revenue growth is +13.3% quarter-over-quarter, while maintaining an operating margin of +12.5% and return on equity of -185.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Amneal Pharmaceuticals Inc (AMRX) Company Overview
About Amneal Pharmaceuticals Inc
Develops and distributes pharmaceutical products globally.
The company operates through three main segments: Generics, Specialty, and AvKARE. It generates revenue by developing and selling a wide range of pharmaceutical products, including generics and specialty drugs, to various customers such as wholesalers, hospitals, and pharmacies. Additionally, the AvKARE segment provides products and services to governmental agencies, enhancing its market reach.
Amneal Pharmaceuticals focuses on treating central nervous system and endocrine disorders, offering innovative treatments like Rytary for Parkinson's disease. Founded in 2002 and headquartered in Bridgewater, New Jersey, the company rebranded from Atlas Holdings, Inc. in 2018, indicating its evolution and commitment to the pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
7,850
CEO
Mr. Chirag K. Patel
Country
United States
IPO Year
2018
Website
amneal.comAmneal Pharmaceuticals Inc (AMRX) Latest News & Analysis
Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have shown performance metrics this year, with comparisons to their respective sectors available for analysis.
Performance comparisons indicate how well Amneal Pharmaceuticals and Aveanna Healthcare are faring against industry peers, impacting investor sentiment and potential stock valuations.
Amneal (AMRX) Upgraded to Strong Buy: Here's Why
14 days agoAmneal (AMRX) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects.
Amneal's upgrade to a Zacks Rank #1 signals strong earnings potential, suggesting increased investor confidence and potential stock price appreciation.
Amneal will participate in upcoming investor conferences, providing an opportunity for investors to engage with the company and gain insights into its operations.
Amneal's participation in investor conferences can indicate potential growth opportunities, reveal strategic insights, and influence stock performance based on investor sentiment.
Amneal has resubmitted its DHE Autoinjector New Drug Application and received U.S. FDA approval for Exenatide, marking its first generic injectable GLP-1 agonist.
Amneal's FDA approval for Exenatide signals a competitive edge in the GLP-1 market, potentially boosting revenue and market share, impacting stock performance positively.
Amneal (AMRX) has reached a 52-week high. Investors are advised to examine the company's fundamentals for insights on potential future gains.
Amneal reaching a 52-week high signals strong market performance, prompting investors to evaluate fundamentals for potential future growth and sustainability of gains.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) will hold its Q3 2024 earnings conference call on November 8, 2024, at 8:30 AM ET, with key executives participating.
Amneal Pharmaceuticals' Q3 2024 earnings call may reveal key financial performance insights that could influence stock valuation, investor sentiment, and future market strategies.
Frequently Asked Questions About AMRX Stock
What is Amneal Pharmaceuticals Inc's (AMRX) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Amneal Pharmaceuticals Inc (AMRX) has a median price target of $10.50. The highest price target is $12.00 and the lowest is $9.00.
Is AMRX stock a good investment in 2025?
According to current analyst ratings, AMRX has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for AMRX stock?
Wall Street analysts predict AMRX stock could reach $10.50 in the next 12 months. This represents a 23.2% increase from the current price of $8.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amneal Pharmaceuticals Inc's business model?
The company operates through three main segments: Generics, Specialty, and AvKARE. It generates revenue by developing and selling a wide range of pharmaceutical products, including generics and specialty drugs, to various customers such as wholesalers, hospitals, and pharmacies. Additionally, the AvKARE segment provides products and services to governmental agencies, enhancing its market reach.
What is the highest forecasted price for AMRX Amneal Pharmaceuticals Inc?
The highest price target for AMRX is $12.00 from Les Sulewski at Truist Securities, which represents a 40.8% increase from the current price of $8.52.
What is the lowest forecasted price for AMRX Amneal Pharmaceuticals Inc?
The lowest price target for AMRX is $9.00 from Chris Schott at JP Morgan, which represents a 5.6% increase from the current price of $8.52.
What is the overall AMRX consensus from analysts for Amneal Pharmaceuticals Inc?
The overall analyst consensus for AMRX is bullish. Out of 12 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.50.
How accurate are AMRX stock price projections?
Stock price projections, including those for Amneal Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
